⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4719059 | 0.73 | — | — | |
| SCHEMBL9575649 | 0.69 | CYP2D6 (0.30) | — | |
| SCHEMBL10378156 | 0.69 | CYP2D6 (0.30) | — | |
| SCHEMBL4720532 | 0.69 | — | — | |
| SCHEMBL1373444 | 0.65 | — | — | |
| SCHEMBL7223828 | 0.65 | — | — | |
| SCHEMBL2007454 | 0.64 | — | — | |
| SCHEMBL9572842 | 0.64 | — | — | |
| SCHEMBL6220571 | 0.64 | — | — | |
| SCHEMBL6220567 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 298 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024104425-A1 | KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广东东阳光药业股份有限公司 | 2024-05-23 | — | — | WO | claimed |
| EP-2318363-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | Nuevolution A/S (DK) | 2011-05-11 | — | — | EP | claimed |
| WO-2009152824-A1 | HETEROCYCLIC DERIVATIVES AS IAP BINDING COMPOUNDS | NUEVOLUTION A/S (DK) | 2009-12-23 | — | — | WO | claimed |
| WO-2005105777-A1 | SUBSTITUTED THIOPHENE AMIDE COMPOUNDS FOR THE TREATMENT OF INFLAMMATION | PHARMACIA & UPJOHN COMPANY LLC (US) | 2005-11-10 | — | — | WO | claimed |
| US-6846827-B1 | Pyrimidine derivatives | ASTRAZENECA AB (SE) | 2005-01-25 | — | — | US | claimed |
| EP-1226126-B1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-01-05 | — | — | EP | claimed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | claimed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | claimed |
| WO-2024104425-A1 | KRAS INHIBITOR COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广东东阳光药业股份有限公司 | 2024-05-23 | — | — | WO | disclosed |
| CN-118047801-A | KRAS inhibitor compound, pharmaceutical composition and application thereof | 广东东阳光药业股份有限公司 | 2024-05-17 | — | — | CN | disclosed |
| EP-3740478-B1 | FUSED IMIDAZOLE DERIVATIVES AS IL-17 MODULATORS | UCB Biopharma SRL (BE) | 2023-11-01 | — | — | EP | disclosed |
| CN-111601799-B | Fused imidazole derivatives as Il-17 modulators | UCB生物制药有限责任公司 | 2023-06-09 | — | — | CN | disclosed |
| US-11472794-B2 | Fused imidazole derivatives as IL-17 modulators | UCB Biopharma SRL (BE) | 2022-10-18 | — | — | US | disclosed |
| US-20220227764-A1 | Imidazopyridine Derivatives as IL-17 Modulators | UCB BIOPHARMA SRL (SOCIETE A RESPONSABILITE LIMITEE) (BE) | 2022-07-21 | — | — | US | disclosed |
| US-6815445-B2 | FOR USE AS FLUORESCENCE DYES AND PROBES | Life Technologies Corporation | 2004-11-09 | — | — | US | disclosed |
| EP-1442027-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2004-08-04 | — | — | EP | disclosed |
| US-20030105111-A1 | Substituted diphenyloxazoles, the synthesis thereof, and the use thereof as fluorescence probes | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2003-06-05 | — | — | US | disclosed |
| WO-2003031419-A1 | SUBSTITUTED DIPHENYLOXAZOLES, THE SYNTHESIS THEREOF, AND THE USE THEREOF AS FLUORESCENCE PROBES | 3-DIMENSIONAL PHARMACEUTICALS, INC. (US) | 2003-04-17 | — | — | WO | disclosed |
| EP-1226126-A1 | PYRIMIDINE DERIVATIVES | AstraZeneca AB (SE) | 2002-07-31 | — | — | EP | disclosed |
| WO-2001027089-A1 | PYRIMIDINE DERIVATIVES | ASTRAZENECA AB (SE) | 2001-04-19 | — | — | WO | disclosed |